Leading Off: Pharmaceuticals in the Dry Eye Disease Pipeline
New innovations targeting dry eye disease (DED) are in the pipeline to enable us to tailor our treatments to the specific underlying causes of DED.
Clinical Scorecard: Leading Off: Pharmaceuticals in the Dry Eye Disease Pipeline
At a Glance
Category Detail
Condition Dry Eye Disease (DED) Key Mechanisms Targeting inflammation and meibomian gland dysfunction Target Population Patients with dry eye disease and related conditions Care Setting Ophthalmology clinics and research settings
Key Highlights
Reproxalap is in phase 3 trials for inflammation reduction in DED. AZR-MD-001 may enhance meibum quality in meibomian gland dysfunction. OCS-02 is an anti-TNFa drop in phase 2 trials for ocular inflammation. Softacort is in phase 4 trials as an anti-inflammatory for meibomian gland dysfunction. Guideline-Based Recommendations
Diagnosis
Assess symptoms and underlying causes of dry eye disease. Management
Consider new pharmacological options tailored to specific DED causes. Monitoring & Follow-up
Evaluate treatment efficacy and adjust based on patient response. Risks
Monitor for potential side effects associated with new treatments. Patient & Prescribing Data
Individuals diagnosed with dry eye disease, particularly those with meibomian gland dysfunction.
Emerging therapies focus on inflammation and meibomian gland function.
Clinical Best Practices
Incorporate warm compress and lid hygiene with anti-inflammatory treatments. Tailor treatment approaches based on individual patient needs. References
